This is a StreetInsider.com Premium Only Page

(APTX) –

Apr 23, 2024 08:00 AM Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

Feb 9, 2024 05:16 PM Form SC 13G/A Aptinyx Inc. Filed by: Artal International S.C.A.

Dec 21, 2023 10:52 AM Form 8-K Aptinyx Inc. For: Dec 21

Dec 18, 2023 05:00 PM Form 8-K Aptinyx Inc. For: Dec 15

Jul 10, 2023 06:05 AM Form 25-NSE Aptinyx Inc. Filed by: Nasdaq Stock Market LLC

Jul 3, 2023 01:31 PM Form 8-K Aptinyx Inc. For: Jun 30

Jun 27, 2023 02:14 PM Form SC 13D/A Aptinyx Inc. Filed by: ADAMS STREET PARTNERS LLC

Jun 2, 2023 04:31 PM Form DEF 14A Aptinyx Inc. For: Jun 30

May 24, 2023 04:50 PM Form S-8 POS Aptinyx Inc.

May 24, 2023 04:44 PM Form S-8 POS Aptinyx Inc.

May 24, 2023 04:44 PM Form RW Aptinyx Inc.

May 24, 2023 04:40 PM Form S-8 POS Aptinyx Inc.

May 24, 2023 04:40 PM Form S-8 POS Aptinyx Inc.

May 23, 2023 08:26 AM Form PRE 14A Aptinyx Inc. For: May 23

May 18, 2023 04:31 PM Form 10-Q Aptinyx Inc. For: Mar 31

May 15, 2023 04:46 PM Form NT 10-Q Aptinyx Inc. For: Mar 31

May 11, 2023 08:02 AM Form 8-K Aptinyx Inc. For: May 10

May 5, 2023 08:02 AM Form 8-K Aptinyx Inc. For: May 04

Apr 28, 2023 04:18 PM Form 10-K/A Aptinyx Inc. For: Dec 31

Apr 25, 2023 09:24 AM Form 8-K Aptinyx Inc. For: Apr 21

Apr 18, 2023 04:16 PM Form 8-K Aptinyx Inc. For: Apr 14

Mar 30, 2023 04:31 PM Form 10-K Aptinyx Inc. For: Dec 31

Mar 30, 2023 04:16 PM Form 8-K Aptinyx Inc. For: Mar 30

Mar 30, 2023 04:08 PM Aptinyx (APTX) Reports Q4, Provides Update on Review of Strategic Alternatives

Mar 30, 2023 04:05 PM Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives

Mar 23, 2023 03:59 PM Aptinyx (APTX) granted European patent related to depression treatment

Mar 16, 2023 04:20 PM Form SC 13D/A Aptinyx Inc. Filed by: Longitude Capital Partners II, LLC

Mar 7, 2023 06:11 AM H.C. Wainwright Downgrades Aptinyx (APTX) to Neutral

Mar 1, 2023 08:32 AM Form 8-K Aptinyx Inc. For: Feb 26

Feb 28, 2023 05:30 PM SVB Leerink Downgrades Aptinyx (APTX) to Market Perform

Feb 27, 2023 04:13 PM Aptinyx (APTX) to Resume Trading at 4:35 p.m.

Feb 27, 2023 04:04 PM Aptinyx (APTX) Says Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia Didn't Hit Endpoints

Feb 27, 2023 04:04 PM Form 8-K Aptinyx Inc. For: Feb 27

Feb 27, 2023 04:03 PM Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

Feb 27, 2023 04:02 PM Aptinyx (APTX) Halted, News Pending

Feb 14, 2023 04:35 PM Form SC 13D/A Aptinyx Inc. Filed by: Longitude Capital Partners II, LLC

Feb 13, 2023 06:06 AM Form SC 13G/A Aptinyx Inc. Filed by: Artal International S.C.A.

Jan 31, 2023 07:47 AM Aptinyx to Present at the SVB Securities Global Biopharma Conference

Jan 20, 2023 10:44 AM Form SC 13G/A Aptinyx Inc. Filed by: Kryzanowski John A

Jan 5, 2023 04:18 PM Form 4 Aptinyx Inc. For: Jan 03 Filed by: KHANNA ASHISH

Jan 5, 2023 04:17 PM Form 4 Aptinyx Inc. For: Jan 03 Filed by: RIEDEL NORBERT G

Jan 5, 2023 04:16 PM Form 4 Aptinyx Inc. For: Jan 03 Filed by: KIDD ANDREW

Dec 8, 2022 04:06 PM Form 8-K Aptinyx Inc. For: Dec 07

Dec 1, 2022 04:07 PM Form 8-K Aptinyx Inc. For: Nov 28

Nov 10, 2022 07:45 AM Aptinyx (APTX) Reports Preclinical Data for NMDA Receptor Modulators

Nov 10, 2022 07:45 AM Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience

Nov 8, 2022 04:32 PM Form 10-Q Aptinyx Inc. For: Sep 30

Nov 8, 2022 04:16 PM Form 8-K Aptinyx Inc. For: Nov 08

Nov 8, 2022 04:05 PM Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

Nov 3, 2022 07:33 AM Aptinyx (APTX) Announces $5.6M NIH Grant to Evaluate NYX-783